Hilco is seeking offers to acquire the intellectual property and tangible assets of MycoNourish Limited (“MycoNourish” or the “Company”) on behalf of the Provisional Liquidator of the Company, Kenneth Craig of Begbies Traynor (Central) LLP.
Founded in 2018, MycoNourish is a UK-based agricultural biotechnology company specialising in precision fungal technologies to improve crop performance, resilience, and sustainability. The Company has developed a unique system for developing and tailoring arbuscular mycorrhizal fungi (AMF), naturally occurring symbiotic organisms that form beneficial relationships with plant roots to enhance nutrient uptake and boost yield quality. Unlike conventional biological products, MycoNourish’s technology enables the customisation of fungal strains to suit specific crops, varieties, and growing conditions, an approach akin to personalised medicine for plants, unlocking meaningful improvements in root structure, plant health, and fertiliser efficiency, particularly in high-value sectors such as short cycle crops, salads, and leafy greens.
Backed by a robust scientific foundation and early grant funding, the Company has invested in significant trial work, protocol development, and IP generation, including an in-progress patent and plant variety rights applications. The resulting prototype formulations are easy to apply, highly adaptable, and designed to integrate seamlessly into existing production systems, whether open field or protected environments.
MycoNourish has gained visibility through winning prizes at Converge Challenge and Scottish EDGE and its participation in leading accelerator programmes including MassChallenge Switzerland, Agri-TechE’s membership events, and Plug and Play AgTech, underscoring its position as an innovator in sustainable crop biotechnology. With an increasing industry push toward sustainable, non-chemical agricultural inputs, this presents a rare opportunity to acquire next-generation microbial IP assets backed by strong proof of concept, technical validation, and near-term commercial viability.
MycoNourish is an emerging leader in the agri-biotech space, known for its precision fungal solutions that improve crop yield, health, and sustainability. Founded on scientific rigour and real-world agronomic outcomes, the brand is underpinned by a strong ethos of evidence-led innovation and environmental responsibility.
The brand has been publicly recognised for its pioneering approach to sustainable agriculture, with coverage in both The National and Life Sciences Scotland highlighting its founder, Dr Peter Orrell, as a “Rising Star” in the sector. These articles showcased MycoNourish’s role in developing tailored fungal technologies to help growers reduce chemical inputs and enhance soil health through natural, symbiotic processes.
Beyond media coverage, MycoNourish has gained visibility through selection into leading programmes, including MassChallenge Switzerland, Agri-TechE, and Plug and Play AgTech, and has cultivated strong research and institutional ties with the James Hutton Institute.
The Company likely holds rights in unregistered trade marks covering the “MycoNourish” brand name and logos.
MycoNourish’s organisational knowledge and know-how are rooted in years of applied research, crop trials, and strain development focused on microbial enhancement of high-value crops. The Company has developed two core product lines, one of which is supported by provisional plant variety rights, with the other underpinned by a draft patent detailing a proprietary fungal formulation and delivery method. While the patent remains unfiled due to prior financial constraints, full documentation exists, with the scope to finalise and submit following minor technical updates.
The Company’s operational knowledge spans microbial selection, plant-microbe interactions, substrate optimisation, and soil-crop compatibility, focusing on a broad spectrum of crops, ranging from high-value short-cycle crops such as salads and leafy greens to field vegetables to arable cereal crops and horticulture, captured across internal protocols, test results, cultivation data, and formulation methodologies stored on the Company’s cloud system, which houses detailed records of crop trials, plant performance metrics, application protocols, and substrate interactions.
MycoNourish holds two provisional Plant Variety Protection rights over key fungal strains developed through its proprietary R&D programme, providing exclusive commercial control and enabling the Company to protect the cultivation, sale, and licensing of its high-performance microbial inoculants, while restricting unauthorised use, reproduction, or derivative applications by third parties.
The Company holds the primary myconourish.com domain name, which is available for acquisition.
The Company holds the copyright in the website content hosted at its domain, showcasing MycoNourish’s innovations.
Rights to Company’s branded social media accounts on LinkedIn, Twitter and Facebook are available for acquisition.
The Company’s tangible assets include sterile lab tools, scientific equipment, live trial crops, and formulation testing stock. Offsite, MycoNourish also holds approximately 67,500kg of substrate used to produce microbes within one of the Company’s product lines.
Full details on the Company’s tangible assets are available via a virtual data room.
All expressions of interest and bids are to be directed to Hilco in writing. A Bid Submission Form is available on request. Please contact Hilco to gain access to a virtual data room of further information on signing a confidentiality agreement.
Hilco is acting as exclusive agent to the Company and its Provisional Liquidator in connection with the proposed sale of some or all of the Company’s assets. The Provisional Liquidator acts as an agent of the Company and without personal liability.
All sales are made strictly on an “as is, where is” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company, its Provisional Liquidator, or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 15% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and its Provisional Liquidator.
